Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Kukje Pharma Co., Ltd. is a leading pharmaceutical company based in South Korea, primarily engaged in the research, production, and distribution of medications and medical supplies. The company's primary function is to innovate and provide accessible healthcare solutions by developing a diverse portfolio of prescription and over-the-counter drugs. Kukje Pharma serves various sectors within the pharmaceutical industry, including the development of treatments for chronic illnesses, antibiotics, and specialty medications. It plays a vital role in the healthcare market by addressing critical medical needs and contributing to the improvement of public health standards. As a dynamic entity in the global pharmaceutical industry, Kukje Pharma leverages cutting-edge research and development capabilities to maintain its competitive edge, emphasizing quality and efficacy in its offerings. The company's significant market presence enhances its ability to impact medical markets domestically in South Korea and internationally, aligning with global health trends and regulatory standards.
₩3,380.00
+₩80.00 (+2.42%)
Live · 11:10 AM
Operating margin is thin at 3.52%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 12.2%, still solid.
Net debt of ₩19.68B represents 10.0x FCF, leverage limits flexibility.
11.6x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩177.97B
▲ +12.2% YoY
Net Income (TTM)
₩5.99B
▲ +9.6% YoY
Op. Margin
3.29%
▼ -0.8pp YoY
ROIC
4.43%
Cash Flow & Balance Sheet
FCF (TTM)
-₩1.22B
▲ +108.1% YoY
Op. Cash Flow (TTM)
₩11.66B
▼ -51.2% YoY
Net Debt
₩19.68B
Cash & Equiv.
₩10.72B
3Y CAGR: +11.5%
3Y CAGR: -27.8%
Continue Research
At a P/E of , A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Kukje Pharma Co. scores 31/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.9%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Kukje Pharma Co. scores 31 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 3.3% operating margin and a 4.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Kukje Pharma Co. pays a regular dividend of about KRW 29.00 per share per year (typically in quarterly installments), a yield of roughly 0.9% at the current price. That is a payout ratio of about 10.2% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 002720.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh 002720.XKRX's valuation and scores 31/100 on quality (lower-quality). It also yields about 0.9%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.